Loading
institutionsInstitution
Garvan Institute of Medical Research / Kinghorn Cancer Centre
One of Australia's leading genomics institutes, whose Kinghorn Cancer Centre with St Vincent's pioneered genomics-guided treatment of pancreatic cancer and rare tumours.
Also called: GarvanThe Kinghorn Cancer CentreSt Vincent's Hospital Sydney
Overview
The Garvan Institute was founded in 1963 at St Vincent's Hospital in Darlinghurst and became a leader in medical genomics, hosting the Kinghorn Centre for Clinical Genomics and, with St Vincent's, The Kinghorn Cancer Centre, opened in 2012 as an integrated research and treatment facility. Garvan investigators led the Australian Pancreatic Cancer Genome Initiative within the International Cancer Genome Consortium (Andrew Biankin, Sean Grimmond), established the Molecular Screening and Therapeutics (MoST) programme for rare and advanced cancers with Omico, and run leading programmes in breast cancer biology, prostate cancer, single-cell and spatial genomics, and epigenetics (Susan Clark). Patients access precision oncology trials, phase 1 studies and germline genomics through the Kinghorn Cancer Centre.
Location
Sydney, AU
Type
research institute · UNSW Sydney
Website
Newsweek 2026 oncology rank
Not in top 300 listing used
OnCo score
#156 · 32 points (0 Newsweek + 0 NCI + 32 from 16 linked objects) · ranking
Research output
From OpenAlex, oncology works in the last five years (2022 to 2026, current year in progress); counted on 2026-10-01.
Matched to Garvan Institute of Medical Research, including child institutions. 196 works · 1,796 citations · 73% open access · 11% clinical trials · 2% reviews.
Oncology works per year
422022
462023
422024
402025
262026
Most works
- Alexander Swarbrick14 works
- Paul Timpson14 works
- Elgene Lim14 works
- Subotheni Thavaneswaran13 works
- Anthony James Gill12 works
- Thomas R. Cox11 works
- Venessa Chin11 works
- David Morgan Thomas11 works
- Marina Pajic11 works
- Adnan M. Nagrial10 works
Most cited
- Pancreatic cancer genomics (APGI)
- MoST precision oncology trials
- Kinghorn Centre for Clinical Genomics
- Epigenetics and single-cell biology
Benjamin Kile
Executive Director
Blood cell biologyMolecular biologyResearch leadership
Blood cell molecular biologist who has led Sydney's Garvan Institute of Medical Research since 2023, sharpening its focus on genomics, immunology and cancer.
Louise Emmett
Director of Theranostics and Nuclear Medicine, St Vincent's Hospital Sydney; Professor, UNSW
PSMA theranosticsNuclear medicineProstate cancer imaging
Nuclear medicine physician who leads ENZA-p and the PSMA imaging trials shaping Australian theranostics.
Susan Clark
Head of the Cancer Epigenetics Laboratory
Cancer epigeneticsDNA methylationProstate and breast cancer
Pioneer of DNA methylation analysis whose Garvan laboratory studies how epigenetic changes drive prostate and breast cancer.
basicNature 20163,029 citations
Genomic analyses identify molecular subtypes of pancreatic cancer
With Moffitt's classical and basal-like split (the squamous and basal-like groups overlap) this fixed the molecular vocabulary of the disease and gave Precision-Panc and the UK's Glasgow group their trial framework.
basicNature 20152,131 citations
Whole genomes redefine the mutational landscape of pancreatic cancer
The genomic case for platinum in BRCA-type pancreatic cancer, four years before POLO built a maintenance strategy on top of it.
translationalNature 20121,721 citations
Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes
The APGI cohort became the backbone of the QCMG whole-genome and subtype papers; ATM's entry here is the origin of its place on today's germline panels.
Similar pages
- TargetKDM6A
Shares Whole genomes redefine the mutational landscape of pancreatic cancer, Genomic analyses identify molecular subtypes of pancreatic cancer, Pancreatic ductal adenocarcinoma, Prostate cancer.
- TermSomatic mutations from exome and genome sequencing (WXS, WGS)
Shares Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes, Genomic analyses identify molecular subtypes of pancreatic cancer, Whole-exome & whole-genome sequencing, Pancreatic ductal adenocarcinoma.
- TrialComboMATCH (EAY191)
Shares Rare cancers, Basket, umbrella, and platform trials, Comprehensive genomic profiling.
- CompanyValius Sciences
Shares Single-cell & spatial profiling, Whole-exome & whole-genome sequencing, Comprehensive genomic profiling.
- CollectionPancreatic Cancer Action Network (PanCAN)
Shares Basket, umbrella, and platform trials, Pancreatic cancer roadmap: from Whipple's operation to gemcitabine, FOLFIRINOX, adjuvant chemotherapy, PARP inhibition, KRAS inhibition, vaccines and the surveillance question, Comprehensive genomic profiling, Pancreatic ductal adenocarcinoma.
- TrialDETERMINE arm 04: trastuzumab with pertuzumab in HER2-amplified or mutated rare cancers
Shares Rare cancers, Basket, umbrella, and platform trials, Comprehensive genomic profiling.
- PersonStefan Fröhling
Shares Whole-exome & whole-genome sequencing, Comprehensive genomic profiling, Sarcomas (soft tissue, bone, GIST).
- InstitutionBeatson West of Scotland Cancer Centre / CRUK Scotland Institute
Shares Genomic analyses identify molecular subtypes of pancreatic cancer, Comprehensive genomic profiling, HR-positive / HER2-negative breast cancer, Pancreatic ductal adenocarcinoma.